Prior to joining ORIC, Mr. Panuwat was Senior Vice President of Business Development at Prothena, where he led partnership activities and established the company’s global research & development collaboration with Celgene. Prior to Prothena, he was Head of Business Development at Medivation, where he led M&A and licensing activities, including the acquisition of talazoparib from BioMarin, until Medivation’s acquisition by Pfizer. He was also previously in corporate development at Questcor until its merger with Mallinckrodt, and spent nearly a decade in the Global Healthcare Investment Banking Group at Merrill Lynch. He holds a BS in biology from Santa Clara University, an MS in physiology and biophysics from Georgetown University and an MBA from UCLA.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
ORIC Pharmaceuticals | Chief Business Officer | Nov 1, 2018 | — | Detail |